CD274 and neoplasm: We conclude that, when considering disease stage and tumor T-cell phenotype status, results indicate that a subset of patients with PD-1/PD-L1 positive tumors, inflamed phenotype, and/or less advanced disease stage could benefit from immunotherapy before traditional treatment.